The norepinephrine transporter (NET), which controls neurotransmission by regulating the reuptake of the neurotransmitter norepinephrine (NE) in the synaptic cleft [1], is an important theranostic target in multiple areas, including the diagnosis of cardiac diseases by monitoring the function of the sympathetic nervous system (SNS), the diagnosis and treatment of neuroendocrine tumors, and the early detection of Parkinson’s disease (PD) [2,3,4]. This evidence concerns the gene SLC6A2 and heart disorder.